<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946853</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB00060626</org_study_id>
    <nct_id>NCT02946853</nct_id>
  </id_info>
  <brief_title>Junctional AV Ablation in CRT-D: JAVA-CRT</brief_title>
  <official_title>Junctional AV Ablation in CRT-D Patients With Atrial Fibrillation (JAVA-CRT Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronization therapy (CRT) is a demonstrably effective device intervention for&#xD;
      patients with heart failure with reduced ejection fraction and specific indication. However,&#xD;
      many patients with heart failure (HF) are unable to maintain sinus rhythm and approximately&#xD;
      30-36% of CRT patients are in atrial fibrillation (AF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate if patients with AF indicated for CRT will have&#xD;
      significant reduction in left ventricular end-systolic volume when randomized to&#xD;
      atrioventricular junction (AVJ) ablation. In this study, subjects will be randomized to&#xD;
      receive CRT-D or CRT-D with AVJ ablation. Randomization will be stratified by enrolling&#xD;
      center (1:1 ratio).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with reduction ≥ 15% in left ventricular end-systolic volume (LVESV)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with improvement in left ventricular ejection fraction (EF)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with improvement in left ventricular end-diastolic volume (LVEDV)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with heart failure hospitalizations</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with implantable cardioverter-defibrillator delivered inappropriate therapy</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with implantable cardioverter-defibrillator delivered appropriate therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of biventricular pacing</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Episodes of ventricular fibrillation following AV junctional ablation as detected on ICD</measure>
    <time_frame>Baseline to one month</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Systolic Heart Failure</condition>
  <condition>Atrial Fibrillation (Permanent)</condition>
  <arm_group>
    <arm_group_label>CRT-D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized at enrollment. Patients in this arm of the study will receive cardiac resynchronization therapy with defibrillator (CRT-D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT-D and AVJ Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm of the study will receive CRT-D and undergo atrioventricular junctional (AVJ) ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrioventricular junctional (AVJ) ablation</intervention_name>
    <description>RF energy delivery to AV node to create complete AV block</description>
    <arm_group_label>CRT-D and AVJ Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac resynchronization therapy - defibrillator</intervention_name>
    <description>Insertion of device capable of providing biventricular pacing and cardiac defibrillation</description>
    <arm_group_label>CRT-D</arm_group_label>
    <arm_group_label>CRT-D and AVJ Ablation</arm_group_label>
    <other_name>CRT-D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Optimal pharmacologic therapy is defined by published guidelines from the American&#xD;
             Heart Association and the American College of Cardiology&#xD;
&#xD;
          -  Initial implantation of CRT-D or prior implantation of CRT-D within one year&#xD;
&#xD;
          -  Ischemic or nonischemic cardiomyopathy&#xD;
&#xD;
          -  LVEF ≤ 35%&#xD;
&#xD;
          -  NYHA class II-IV (ambulatory)&#xD;
&#xD;
          -  QRS ≥ 120 ms for LBBB and ≥ 150 ms for non-LBBB patients&#xD;
&#xD;
          -  Continuous AF &gt; 3 months when no further efforts to restore sinus rhythm are feasible&#xD;
             or pursued&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ventricular rate &gt; 110 bpm at rest despite maximal medical therapy&#xD;
&#xD;
          -  Ventricular rate &lt; 50 bpm at rest&#xD;
&#xD;
          -  Heart block/symptomatic bradycardia that necessitates permanent pacing&#xD;
&#xD;
          -  Acute coronary syndrome or coronary artery bypass surgery within 12 weeks&#xD;
&#xD;
          -  Severe aortic or mitral valvular heart disease&#xD;
&#xD;
          -  Prior AVJ ablation&#xD;
&#xD;
          -  Any medical condition likely to limit survival to &lt; 1 year&#xD;
&#xD;
          -  Patients with ACC/AHA Stage D refractory Class IV symptoms listed for transplant or&#xD;
             requiring inotropic support&#xD;
&#xD;
          -  Contraindication to systematic anticoagulation&#xD;
&#xD;
          -  Renal failure requiring dialysis&#xD;
&#xD;
          -  AF due to reversible cause e.g. hyperthyroid state&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Participation in other clinical trials that will affect the objectives of this study&#xD;
&#xD;
          -  History of non-compliance to medical therapy&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent&#xD;
&#xD;
          -  Patients with short-lived AF or those in sinus rhythm are ineligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Jonathan S. Steinberg</investigator_full_name>
    <investigator_title>Professor of Medicine - Cardiology</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>CRT</keyword>
  <keyword>AV Junction Ablation</keyword>
  <keyword>LVESV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 20, 2021</submitted>
    <returned>August 12, 2021</returned>
    <submitted>September 18, 2021</submitted>
    <submission_canceled>September 18, 2021</submission_canceled>
    <submitted>November 2, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

